ライフサイエンスコーパス: hot flash

1 te the effect of a hypnosis intervention for hot flashes.

2 ic calcification compared with women without hot flashes.

3 ively) are associated with tamoxifen-induced hot flashes.

4 rsus daily oral venlafaxine as treatment for hot flashes.

5 is a nonhormonal agent that also can reduce hot flashes.

6 and newer antidepressants effectively reduce hot flashes.

7 effects than did pills for the treatment of hot flashes.

8 ystemic therapy for breast cancer experience hot flashes.

9 viously demonstrated that paroxetine reduces hot flashes.

10 that red clover has no benefit for treating hot flashes.

11 uoxetine resulted in a modest improvement in hot flashes.

12 pressants, such as venlafaxine, can diminish hot flashes.

13 symptoms, including number and intensity of hot flashes.

14 related antidepressants for the treatment of hot flashes.

15 rtant to evaluate nonhormonal treatments for hot flashes.

16 bind to estrogen receptors, could alleviate hot flashes.

17 nt for side effects, and 84% of patients had hot flashes.

18 most common adverse effect of raloxifene is hot flashes.

19 esent an efficacious new method to alleviate hot flashes.

20 afaxine nor soy proved effective in reducing hot flashes.

21 causing hormonally mediated symptoms such as hot flashes.

22 and were significantly less likely to cause hot flashes.

23 quency multiplied by the average severity of hot flashes.

24 al treatments with demonstrated efficacy for hot flashes.

25 effective, well-tolerated agent in managing hot flashes.

26 antidepressants and gabapentin for treating hot flashes.

27 given venlafaxine or placebo for control of hot flashes.

28 ary promising data that pregabalin decreased hot flashes.

29 Mild nausea (20% of patients) and hot flashes (20%) were the most common drug-related adve

30 s were fatigue (50%), arthralgias (53%), and hot flashes (59%).

31 Most reported complications: hot flashes (70%), nausea (34%), and erectile dysfunctio

32 Hot flashes (75% v 46%) and tumor flare (16% v 3%) were

33 Women who suffered at least two hot flashes a day for 1 month or longer were eligible.

34 ons have been investigated as treatments for hot flashes, a major clinical problem in many women.

35 The decrease in hot flashes achieved with progestational agents is simil

36 The primary end point, the change in hot flash activity from baseline to week 4, for each age

37 to detect a clinically meaningful change in hot flash activity.

38 tify efficacious agents for the reduction of hot flash activity.

39 The primary endpoint was average daily hot-flash activity (number of flashes and a score combin

40 GP, with fewer adverse effects for managing hot flashes among breast cancer survivors; however, thes

41 oacupuncture (EA) versus gabapentin (GP) for hot flashes among survivors of breast cancer, with a spe

42 ating therapy in a perimenopausal woman with hot flashes and discontinuing estrogen use in a long-ter

43 Significant associations between hot flashes and flow-mediated dilation (beta=-0.97; SE,

44 ective integrative intervention for managing hot flashes and improving quality of life in women with

45 was to examine relations between menopausal hot flashes and indices of subclinical cardiovascular di

46 Pregabalin decreases hot flashes and is reasonably well tolerated.

47 months, exemestane was associated with fewer hot flashes and less vaginal discharge than tamoxifen, b

48 omparable effects on treatment of menopausal hot flashes and may have similar short-term adverse effe

49 nificant decrease in the perceived burden of hot flashes and night sweats (problem rating scale of th

50 trolled clinical trials of CAM therapies for hot flashes and other menopausal symptoms were identifie

51 s recorded number, duration, and severity of hot flashes and overall quality-of-life score (on a 10-p

52 d with modest reductions in the frequency of hot flashes and vaginal dryness but no significant reduc

53 l strips, the patient reported resolution of hot flashes and, for the first time, oestradiol was dete

54 constipation), episodic dry eyes and mouth, hot flashes, and erectile dysfunction.

55 sed for psychiatric conditions or to relieve hot flashes, and these should be avoided in tamoxifen us

56 ity of newer antidepressants for alleviating hot flashes, antidepressants do not work adequately enou

57 ry artery and aortic calcification, reported hot flashes (any/none, previous 2 weeks), and a blood sa

58 Hot flashes are a common and debilitating symptom among

59 Hot flashes are a common problem for which effective and

60 Vasomotor hot flashes are a common problem in menopausal women.

61 Hot flashes are a significant problem for many breast ca

62 omen with hot flashes, it is unknown whether hot flashes are associated with subclinical cardiovascul

63 Hot flashes are common and frequently lead to drug disco

64 tients, other nonhormonal means for treating hot flashes are required.

65 Hot flashes are the most frequently reported side effect

66 outcomes were the frequency and severity of hot flashes assessed by prospective daily diaries at wee

67 resulted in fewer and less severe menopausal hot flashes at 8 weeks of follow-up.

68 Gabapentin is effective in the control of hot flashes at a dose of 900 mg/day, but not at a dose o

69 Participants did not experience hot flashes at baseline (n = 896).

70 ifen use, reported frequency and duration of hot flashes at baseline, and dropout rates.

71 nts (1 to 4 for mild to very severe) to each hot flash based on severity and then adding the points f

72 proximately 80% of 297 participants reported hot flashes before or during the first year of tamoxifen

73 on the frequency, severity, and duration of hot flashes before the start of the study and during wee

74 Secondary outcomes were hot flash bother, recorded on daily diaries, and clinica

75 Black cohosh has been used to treat hot flashes, but definitive clinical data about efficacy

76 Body weight is related to hot flashes, but little is known about the effect of wei

77 Soy seems to have modest benefit for hot flashes, but studies are not conclusive.

78 ffective for menopausal symptoms, especially hot flashes, but the lack of adequate long-term safety d

79 ed as alternatives to hormonal therapies for hot flashes, but there is a paucity of data supporting t

80 The three gabapentin trials decreased hot flashes by 35% to 38% compared with the correspondin

81 Gabapentin seems to decrease hot flashes by approximately 50% in women with inadequat

82 e MPA patients (81 of 109) had a decrease in hot flashes by more than 50% from baseline (P < .0001).

83 Hot flashes can be a major problem for patients with a h

84 Hot flashes can be a prominent clinical problem for brea

85 Hot flashes can be a prominent problem in women with a h

86 Hot flashes can be managed with venlaxafine, gabapentin,

87 Hot flashes can be troublesome, especially when hormonal

88 Hot flashes can cause discomfort, disrupted sleep, anxie

89 Hot flashes can cause significant morbidity in postmenop

90 understood; however, some symptoms, such as hot flashes, certainly begin in the perimenopause.

91 s significantly reduced the weekly number of hot flashes compared with placebo (CEE, 1 trial: mean ch

92 both agents would more effectively alleviate hot flashes, compared with gabapentin alone, in patients

93 The primary end point was change in the hot flash composite score (HFCS) between SA and PP at we

94 Mean placebo-adjusted reduction in hot flash composite scores were -4.7 (95% confidence int

95 trial in which 118 patients with inadequate hot flash control on an antidepressant were randomly ass

96 y approximately 50% in women with inadequate hot flash control who were using an antidepressant.

97 abapentin alone, in patients with inadequate hot flash control with an antidepressant alone.

98 The reductions in mean daily hot flash count at 12 weeks were similar for the Promens

99 Hot flash data were collected by daily diary questionnai

100 -completed diaries was undertaken to compare hot flash data with toxicity and quality-of-life (QOL) e

101 The number of daily hot flashes decreased compared with placebo in meta-anal

102 th groups exhibited significant decreases in hot flashes, depressive symptoms, and other quality-of-l

103 Participants completed baseline daily hot flash diaries for one week prior to the start of the

104 One-week hot flash diaries were collected to calculate a hot flas

105 ng which time they completed validated daily hot flash diaries.

106 assigned to placebo; 69 completed all three hot flash diaries.

107 ded all randomized participants who provided hot flash diary data, the mean difference in hot flash f

108 Participants kept a daily hot flash diary during a baseline week and then during t

109 nd at 30 and 60 days, they completed a 4-day hot flash diary.

110 Newly reported or worsening hot flashes did not negatively influence test scores or

111 redict which women are most likely to suffer hot flashes during tamoxifen treatment.

112 ere used to measure potential toxicities and hot flashes during the baseline week and the two subsequ

113 re used to compare the primary and secondary hot flash efficacy end points between pregabalin treatme

114 to provide reasonable estimates of eventual hot flash efficacy to screen potential agents for more d

115 n but were significantly more likely to have hot flashes, even when analyses controlled for HRT and r

116 RCTs involving eight symptoms (pain, nausea, hot flashes, fatigue, radiation-induced xerostomia, prol

117 Search terms were hot flash/flush, menopause, and climacteric, combined wi

118 14 bothersome hot flashes per week recorded hot flashes for 7 days before starting treatment and wer

119 of detectable disease and 14 or more weekly hot flashes for at least 1 month.

120 erceived need for nonhormonal treatments for hot flashes for breast cancer survivors.

121 eatment period showed a similar reduction in hot flash frequencies (25% v 22%; P = .90) for the two s

122 was an approximately 50% median reduction in hot flash frequencies (54%; 95% CI, 34% to 70% for combi

123 Hot flash frequencies and scores (frequency times mean s

124 6 weeks; daily diaries were used to measure hot flash frequencies and severities.

125 iaries, and clinical improvement (defined as hot flash frequency >/=50% decrease from baseline).

126 group reported a decrease of at least 50% in hot flash frequency (P = .009) at the 8-week follow-up.

127 Paroxetine 10 mg reduced hot flash frequency and composite score by 40.6% and 45.

128 Paroxetine 20 mg reduced hot flash frequency and composite score by 51.7% and 56.

129 mg and 20 mg compared to placebo in reducing hot flash frequency and composite score.

130 Hot flash frequency and hot flash score (frequency multi

131 asure was a bivariate construct representing hot flash frequency and hot flash score, analyzed by a c

132 e was a bivariate construct that represented hot flash frequency and hot flash score, which was analy

133 The mean reductions in the hot flash frequency composite score from baseline to wee

134 Hot flash frequency in breast cancer patients was reduce

135 true acupuncture versus sham acupuncture on hot flash frequency in women with breast cancer.

136 r therapies with sufficient trials reporting hot flash frequency outcomes.

137 This reduction in hot flash frequency persisted for up to 6 months after t

138 hot flash diary data, the mean difference in hot flash frequency reduction was 1.41 (95% CI, 0.13-2.6

139 Mean (SD) daily hot flash frequency was 9.78 (5.60) at baseline.

140 Hot flash frequency was evaluated at baseline, at 6 week

141 The mean decrease in hot flash frequency was greater in the clonidine group t

142 Mean hot flash frequency was reduced 17% on black cohosh and

143 By week 6, the mean daily hot flash frequency went from 7.1 to 3.8 (mean reduction

144 completed a daily questionnaire documenting hot flash frequency, intensity, and perceived side effec

145 was associated with significant decreases in hot-flash frequency and severity.

146 on of treatment with a >or= 75% reduction in hot flashes from baseline.

147 y post-menopausal temperature dysregulation (hot flashes), glucose intolerance, increased appetite an

148 Women with hot flashes had reduced flow-mediated dilation and great

149 Standard therapy for hot flashes has been hormone replacement with estradiol

150 Hot flashes (HF) affect a large proportion of breast can

151 ashes (HF-) compared with that in women with hot flashes (HF+), possibly through lowered concentratio

152 ondary breast cancer events in women without hot flashes (HF-) compared with that in women with hot f

153 Hot flashes (HFs) affect up to 75% of menopausal women a

154 Among participants who reported hot flashes (HFs) at baseline (n = 3,375), those assigne

155 ateral oophorectomy were less likely to have hot flashes if they were on HRT, but women with 0-1 ovar

156 ent was well tolerated with mild to moderate hot flashes in 18 of 32 patients (56%) at all dose level

157 Hypnosis appears to reduce perceived hot flashes in breast cancer survivors and may have addi

158 The soy product did not alleviate hot flashes in breast cancer survivors.

159 to defining new treatment opportunities for hot flashes in cancer survivors, considerable experience

160 ntion studies have been conducted to relieve hot flashes in men.

161 improve women's health, especially to reduce hot flashes in menopausal women, alleviate the symptoms

162 re associated with greater odds of reporting hot flashes in models adjusted for age, site, race/ethni

163 mg/d, is effective against tamoxifen-induced hot flashes in postmenopausal women with breast cancer.

164 ignificant increases in hot flashes, whereas hot flashes in the acupuncture group remained at low lev

165 rovide better non-hormonal means of treating hot flashes in the future.

166 Prior progestin studies treating hot flashes in women have been short duration and single

167 entions that appear effective for decreasing hot flashes in women may not always turn out to be effec

168 ss the efficacy of gabapentin in controlling hot flashes in women with breast cancer.

169 s drug should be considered for treatment of hot flashes in women with breast cancer.

170 Paroxetine is an effective treatment for hot flashes in women with or without a prior breast canc

171 uga racemosa 20 mg BID) for the treatment of hot flashes in women.

172 r mean hot flash score (P = .03), with daily hot flashes increasing from baseline by 33% compared wit

173 Reliable and valid definitions of hot flash intensity were developed from patient-reported

174 e reserve, depressive symptoms, fatigue, and hot flash interference did not moderate the impact of AD

175 evaluation of this compound for alleviating hot flashes is indicated.

176 ts adverse vascular changes among women with hot flashes, it is unknown whether hot flashes are assoc

177 hysical function, fatigue, urinary problems, hot flashes, libido, and erectile function.

178 ansition (LR+ range, 1.53-2.13), symptoms of hot flashes (LR+ range, 2.15-4.06), night sweats (LR+ 1.

179 Most breast cancer survivors experience hot flashes; many use complementary or alternative remed

180 Hot flashes may mark adverse underlying vascular changes

181 tcome measure was the change in frequency of hot flashes measured by participant daily diaries.

182 group (34%; 95% CI, 22%-46%; P =.74) reduced hot flashes more rapidly.

183 thin 4 weeks of therapy initiation, decrease hot flashes more than placebo.

184 ovide any evidence that black cohosh reduced hot flashes more than the placebo.

185 s also included reported vasomotor symptoms (hot flashes, night sweats) and serum levels of follicle-

186 though most women report vasomotor symptoms (hot flashes, night sweats) during midlife, their etiolog

187 Hot flashes, night sweats, and vaginal dryness.

188 Hot flashes occur in approximately 80% of androgen-depri

189 Women were required to have at least 10 hot flashes of any severity or at least five severe epis

190 eported anxiety, depression, interference of hot flashes on daily activities, and sleep were observed

191 easures were self-reports of interference of hot flashes on daily activities.

192 E was associated with a minimal decrease in hot flashes (one less hot flash per day than was seen wi

193 e odds ratios for all symptoms, particularly hot flashes or night sweats (odds ratios = 2.06-4.32), w

194 Hot flashes or night sweats, urine leakage, and stiffnes

195 plement had a clinically important effect on hot flashes or other symptoms of menopause.

196 e management of menopausal symptoms, such as hot flashes or vaginal dryness.

197 orted more severe musculoskeletal (P = .02), hot flash (P = .02), and cognitive problems (P = .006) a

198 Hot flashes (P = .0007), pain with sexual intercourse (P

199 The tamoxifen group had higher levels of hot flashes (P = .002), cognitive problems (P = .016), a

200 a minimal decrease in hot flashes (one less hot flash per day than was seen with a placebo) (P < or

201 reduction was 1.41 (95% CI, 0.13-2.69) fewer hot flashes per day at week 8 among women taking escital

202 CI, 3.74-5.47) and 3.20 (95% CI, 2.24-4.15) hot flashes per day in the escitalopram and placebo grou

203 ue acupuncture was associated with 0.8 fewer hot flashes per day than sham at 6 weeks, but the differ

204 mean 1.59 (95% CI, 0.55-2.63; P = .02) more hot flashes per day than women in the placebo group.

205 The mean number of hot flashes per day was reduced from 8.7 (standard devia

206 th breast cancer who were having two or more hot flashes per day were randomly assigned placebo, gaba

207 ith breast cancer experiencing three or more hot flashes per day were randomly assigned to receive ei

208 4.5] years since menopause) experiencing 8.1 hot flashes per day.

209 menopausal women with at least 14 bothersome hot flashes per week recorded hot flashes for 7 days bef

210 have reported that they averaged at least 14 hot flashes per week; they could have received tamoxifen

211 As hot flash physiology is not definitively understood, it

212 es were associated with improvement in daily hot flashes (pooled mean difference of changes, -0.79 [-

213 iated with a decrease in the number of daily hot flashes (pooled mean difference of changes, -1.31 [9

214 ing, body mass index, premenstrual syndrome, hot flashes, poor sleep, health status, employment, and

215 as impotence, decreased libido, fatigue, and hot flashes primarily affect the patient's quality of li

216 ments also consistently alleviate menopausal hot flashes provided they contain sufficient amounts of

217 Patients completed daily hot-flash questionnaire diaries.

218 This study saw no significant additional hot flash reduction from continuation of the antidepress

219 was able to show a statistically significant hot flash reduction with vitamin E compared to a placebo

220 provement in secondary outcomes, such as the Hot Flash Related Daily Interference Scale, was statisti

221 9) and did not experience moderate to severe hot flashes relative to women heterozygous or homozygous

222 o identify effective nonhormonal options for hot flash relief.

223 Body fat gains are associated with greater hot flash reporting during the menopausal transition.

224 Hot flashes represent a significant clinical problem for

225 Hot flashes represent a substantial clinical problem for

226 Hot flash frequency and hot flash score (frequency multiplied by average severit

227 flash diaries were collected to calculate a hot flash score (frequency x severity) before and 1, 4,

228 ant chemotherapy had a four-fold increase in hot flash score (from 5.9 to 23.6; P = .003) compared wi

229 ng tamoxifen had a significantly higher mean hot flash score (P = .03), with daily hot flashes increa

230 Basic summary statistics were produced for hot flash score and frequency using the following three

231 The primary outcome was hot flash score at the end of treatment (week 12), calcu

232 Hot flash score changes available for 163 patients durin

233 for this study was the change-from-baseline hot flash score during treatment week 6 between the 150

234 demonstrated a significantly greater marked hot flash score improvement with fluoxetine than placebo

235 ing black cohosh reported a mean decrease in hot flash score of 20% (comparing the fourth treatment w

236 In both groups, the hot flash score peaked at 3 months and decreased thereaf

237 re was associated with a significantly lower hot flash score than enhanced self-care at the end of tr

238 A hot flash score was calculated at each time point.

239 nstruct representing hot flash frequency and hot flash score, analyzed by a classic sums and differen

240 uct that represented hot flash frequency and hot flash score, which was analyzed by a classic sums an

241 t was the change from baseline to 6 weeks in hot flash score.

242 d hot flushes in a daily diary by use of the Hot-Flash Score, devised by Sloan and colleagues, and ni

243 he study had a greater than 50% reduction in hot flash scores (frequency times severity) during the f

244 By the end of the treatment period, hot flash scores (frequency x average severity) decrease

245 By the end of the first treatment period, hot flash scores (frequency x average severity) decrease

246 Data for hot flash scores and frequencies showed significant impr

247 faxine, fluoxetine, and sertraline decreased hot flash scores by 41%, 33%, 13%, and 3% to 18% compare

248 alleles was associated with higher baseline hot flash scores compared with those who had other haplo

249 2-02 GG genotypes had 4.6 times increases in hot flash scores than other postmenopausal women (56 v 1

250 Reductions in mean hot flash scores were 2.0 (23%), 7.0 (49%), 7.7 (50%), a

251 Hot flash scores were measured by assigning points (1 to

252 reatment, and then had a baseline week where hot flash scores were recorded without treatment.

253 Median weekly hot flash scores were reduced by 55% from baseline durin

254 ring the sixth week after random assignment, hot flash scores were reduced by 55% in the venlafaxine

255 After week 4 of treatment, median hot flash scores were reduced from baseline by 27% (95%

256 Reductions in hot flash severity scores were significantly greater in

257 The percentage decreases in hot-flash severity score between baseline and weeks 4 an

258 The primary end point was hot flash symptom severity score (HFSSS), defined as num

259 t and other therapies in treating menopausal hot flash symptoms.

260 d risk for venous thromboembolic disease and hot flashes; tamoxifen increased risk for endometrial ca

261 well tolerated and more effectively reduces hot flashes than does venlafaxine.

262 e soy product was more effective in reducing hot flashes than the placebo.

263 ved who were on HRT were more likely to have hot flashes than those not on HRT.

264 were significantly more likely to experience hot flashes than were white women, independent of HRT st

265 less likely to experience tamoxifen-induced hot flashes than women who carried at least one ESR-02 G

266 eases) experienced more menopausal symptoms (hot flashes) than did women in the other groups with est

267 al symptoms (eg, joint pains, headaches, and hot flashes) than healthy women.

268 are, for example, treatment of depression or hot flashes, than did those in the control group (adjust

269 and other newer antidepressants for treating hot flashes, the present trial was developed.

270 reported declines in number and intensity of hot flashes; the differences between the groups were not

271 e is an effective non-hormonal treatment for hot flashes, though the efficacy must be balanced agains

272 Gastrointestinal side effects, hot flashes, thromboembolic events, and infections vary

273 severity score (HFSSS), defined as number of hot flashes times severity.

274 Although oestrogen can alleviate hot flashes to a large extent in most patients, there ha

275 re, vitamin E, and acupuncture do not affect hot flashes; two trials have shown that red clover has n

276 hat provided data on treatment of menopausal hot flashes using 1 or more nonhormonal therapies.

277 he experienced menopausal symptoms including hot flashes, vaginal dryness, and sexual dysfunction.

278 ure, a further reduction in the frequency of hot flashes was seen.

279 whom 85% were on tamoxifen, 40% had over 63 hot flashes/week, and 75% had vasomotor symptoms for >or

280 Hot flashes were associated with significantly lower flo

281 Women with bothersome hot flashes were entered onto this trial, were randomly

282 Rates of fatigue, diarrhea, and hot flashes were higher in the enzalutamide group.

283 Hot flashes were more common in the experimental arm: 63

284 Sixty female breast cancer survivors with hot flashes were randomly assigned to receive hypnosis i

285 Moderate-to-severe hot flashes were reported for 11% of patients receiving

286 e group experienced significant increases in hot flashes, whereas hot flashes in the acupuncture grou

287 Up to 75% of women experience hot flashes, which can negatively impact quality of life

288 of disease relapse and a lower incidence of hot flashes, which is consistent with our previous obser

289 requencies showed significant improvement in hot flashes with citalopram over placebo, with no signif

290 erated and effective mind-body treatment for hot flashes would be of great value.

291 We hypothesized that women with hot flashes would show reduced flow-mediated dilation an